Notícias e Atividades da Rakuten Medical

A Rakuten Medical pertence à Rakuten.

Rakuten é uma das ...

• Forbes Global 2000 (#909);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Rakuten é uma empresa listada sob o símbolo 4755 (JP).

Rakuten tem presença direta em 9 países.

Rakuten possui 19 subsidiárias incluindo Cartera Commerce, Kobo e Rakuten Advertising.

Eles estão dentro:

• Varejo40%
• Telecomunicações15%
• Outro45%

Fusão, aquisição e financiamento envolvendo Rakuten.

• Rakuten Medical acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 8 de janeiro de 2026).

Veja o organograma con seus 25 executivos principais

Biografias mais buscadas da Rakuten Medical

• Hiroshi Mikitani, Chief Executive Officer and Chairman of the Board
• Nitin Nohria, Chairman of the Board
• Kentaro Hyakuno, Director

Criar um alerta
para seguir os movimentos de executivos da Rakuten Medical.

Rakuten possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• Ona Therapeutics acaba de anunciar uma arrecadação de fundos de 87 milhões de dólares. (publicado em 5 de junho de 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (publicado em 4 de junho de 2026).
• Oak Hill Bio acaba de anunciar uma arrecadação de fundos de 33 milhões de dólares. (publicado em 4 de junho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Patrick Enright - Director da CuraSen Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Rakuten Medical

• Commencement of Investigator-Initiated Trial (IIT) of Photoimmunotherapy in Gynecologic Cancers in Japan - Rakuten Medical - To conquer cancer.
• Rakuten Medical Announces Commercialization of Medical Devices “BioBlade™ Laser WR” and “BioBlade SideFire Diffuser ™” in Japan for Photoimmunotherapy for Head and Neck Cancer based upon its Alluminox Platform - Rakuten Medical - To conquer cancer.
• Rakuten Medical Presented Research Results of Preclinical Studies for PD-L1-Targeted Photoimmunotherapy at The 83rd Annual Meeting of The Japanese Cancer Association 2024 - Rakuten Medical - To conquer cancer.
• Rakuten Medical Announces New Management Team to Drive the Next Phase of Growth and Innovation - Rakuten Medical - To conquer cancer.
• Rakuten Medical Announces Poster Presentation and Booth Exhibition at ASCO 2024 Annual Meeting - Rakuten Medical - To conquer cancer.
• Rakuten Medical Announces Recent Interim Data from Phase 1b/2 Clinical Trial of ASP-1929 Photoimmunotherapy in Combination with anti-PD-1 for First Line Recurrent and/or Metastatic Head and Neck Cancer to be Presented at ASCO 2024 - Rakuten Medical - To c
• Rakuten Medical’s Poster Presentation at AACR 2024 Demonstrates Reduction in Photoimmunotherapy-induced Edema in Mice with COX-2 Inhibition - Rakuten Medical - To conquer cancer.
• Rakuten Medical’s Upcoming Poster Presentation at AACR 2024: New Findings in Mouse Study to Manage Edema Associated with Photoimmunotherapy based on the Alluminox™ Platform - Rakuten Medical - To conquer cancer.
• Rakuten Medical Closes $119 Million Series E Financing to Further Develop its Alluminox™ Platform - Rakuten Medical - To conquer cancer.
• Over 20 Presentations on Alluminox Treatment (Photoimmunotherapy) at International Conferences in 2023 - Rakuten Medical - To conquer cancer.
• View more press releases Close

Redes sociais sobre Rakuten Medical

• Rakuten Medical na Wikipedia, Google News e Yahoo Finance
• Rakuten Medical na LinkedIn, X (Twitter) e YouTube